REYON Pharmaceutical has gained large-scale chemical drug production capacity with the completion of construction of the Chungju chemical plant.
REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) announced on November 1 that it had completed the construction of the Chungju chemical plant for the mass production of chemical drugs such as injections and solid oral dosage forms.
The company plans to proceed with qualification, validation, and GMP certification as quickly as possible to begin operating the chemical plant in full swing.
[A photograph of REYON Pharmaceutical’s Chungju chemical plant taken by a drone (November 1)]
REYON Pharmaceutical’s Chungju chemical plant built with a budget of KRW 210 billion since February 2019 is located in Daesowon-myeon, Chungju-si, Chungcheongbuk-do Province. It was built on a lot spanning 1,000 m2 (approx. 22,851 pyeong) in area, and it has a gross floor area of 52,000 m2 (approx. 15,800 pyeong).
The Chungju chemical plant was built as a smart factory, just like REYON’s bio plant, and it consists of cGMP production facilities, where liquid and freeze-dried injections and solid oral dosage forms will be mass-produced.
It has a production capacity of 48 million vials of liquid injections and 9 million vials of freeze-dried injections per year, and it can produce up to 1.14 billion tablets of solid oral dosage forms per year.
Unlike existing factories, the Chungju chemical plant has been built as a modular manufacturing site with a separate space for each formulation, and utility systems have been installed on an empty lot nearby, which will make it possible to add production lines for various formulations and boost the production capacity in a timely manner according to market demand.
It is also a smart factory where the operation can be optimized by integrated management of the IT systems.
REYON Pharmaceutical plans to mass-produce injections and oral medicines in solid dosage forms at the Chungju chemical plant in the short run by manufacturing its own products and pursuing a business as a contract manufacturing organization (CMO). In the long run, it plans to produce dietary supplements and natural medicines to advance into the related markets in developed countries.
This is part of the strategy is to maximize synergy with the Jincheon plant (chemical plant) and the Chungju bio plant.
“The Chungju chemical plant is an unprecedented plant in the world that can maximize the synergy between bio and chemical drug production. We are delighted to announce that the completion of the plant construction has created the foundation for us to make a quantum jump for the next 100 years beyond our 66th anniversary,” said REYON Pharmaceutical CEO Yoo Yong-hwan, who also added, “Based on the bio and chemical drug production platform created by the Chungju plants, we will do our best, together with all of our executives and employees, to become a global pharmaceutical company in the future.”
A company official explained that the completion ceremony for the Chungju plants will be held in late November or early December after determining the number of guests in consideration of the COVID-19 situation.
